繁體
简体中文
繁體中文

Sanofi GCVRZ 深 滬

已收盤 03-26 16:00:00 美东时间

0.8711

0.000

0.00%

华盛通華盛通
立即下載
  • 最 高--
  • 今 開--
  • 成交量 0股
  • 最 低 --
  • 昨 收 0.8711
  • 總市值 1113.52亿
  • 52周最高 0.882
  • 市盈率 靜 --
  • 換手率 0.00%
  • 52周最低 0.43
  • 委 比 0.00%
  • 總股本 1278.30亿
  • 歷史最高 0.882
  • 量 比 0
  • 振 幅 0.00%
  • 歷史最低 0.153
  • 每 手 1
  • 風險率 0.00%

個股概要

財務分析

公司資料

相關新聞

分紅派息

  • 分時圖
  • 日k
  • 周k
  • 月k

相關新聞

更多
  • Potential Sanofi-Insmed Deal: Analysts Split on Financial Strain Versus Pipeline Gains

    French pharmaceutical giant Sanofi SA (NASDAQ:SNY) is reportedly exploring a potential acquisition of  Insmed Inc. (NASDAQ:INSM). As per a Thursday Bloomberg report, the potential acquisition comes as Sanofi seeks new growth opportunities to reduce its reliance on blockbuster drug Dupixent. Preparin...

    11-21 01:14

  • Sanofi’s Ulcerative Colitis Trial Ends Without Reported Results

    Sanofi ($SNYNF) announced an update on their ongoing clinical study. Study Over...

    11-21 00:30

  • 3 AI Pharma Stocks Retail Investors Are Watching for R&D Efficiency

    AI is starting to reshape how big pharma searches for the next blockbuster drug, and that shift is pulling fresh attention to a handful of companies that talk openly about using algorithms, machine learning and computational chemistry in their pipelines. If you care about where capital may cluster next, ignoring this theme risks missing a potential re-rating story. This article unpacks three AI-exposed giants from the screener and explains why th

    11-20 22:09

  • Could FDA Backing Change The Bull Case For Recursion Stock (RXRX)

    Recursion Pharmaceuticals reported FDA alignment on the design of its registrational Phase 3 trial for REC-4881 in familial adenomatous polyposis, including a composite event free survival primary endpoint that counts excision of adenomas 10 mm or larger across the gastrointestinal tract. The planned Phase 3 trial, informed by AI driven discovery and TUPELO data, targets a disease with no approved pharmacologic therapies and could be important fo

    11-20 11:14

  • 赛诺菲考虑发起制药行业数年来规模最大并购之一

    (来源:欧洲并购与投资) 赛诺菲考虑发起制药行业数年来规模最大并购之一 图片来源于网络 法国制药企业赛诺菲(Sanofi)上个月释放出扩大业务发展和...

    11-20 11:01

  • 'Sanofi Weighs Takeover of US Drugmaker Insmed' - Bloomberg

    https://www.bloomberg.com/news/articles/2026-11-19/sanofi-weighs-takeover-of-us-drugmaker-insmed

    11-19 23:17

  • Sanofi Weighs Takeover Of Us Drugmaker Insmed

    Sanofi Weighs Takeover Of Us Drugmaker Insmed

    11-19 23:16

  • Retension Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Corporate Update

    Retension Pharmaceuticals completed its IPO in October 2026, raising $51.75 million to support the development of RTN-001 for uncontrolled hypertension. The Phase 2b clinical trial is ongoing, with topline data expected in early 2027. The company has strengthened its leadership team and formed a Scientific Advisory Board of hypertension experts. Third-quarter 2026 financials showed a net loss of $5.9 million, with increased R&D and G&A expenses d...

    11-18 13:00

  • 赛诺菲Frexalimab注射液启动Ⅲ期临床 适应症为多发性硬化

    药物临床试验登记与信息公示平台数据显示,Sanofi-Aventis Recherche & Développement、赛诺菲(中国)投资有限公司、...

    11-18 12:31

  • Windward Bio Announces Pricing of Initial Public Offering

    Windward Bio Group AG announced the pricing of its initial public offering of 10,294,117 common shares at $17.00 per share, with a potential additional 1,544,117 shares via underwriters' option. The gross proceeds, including a concurrent private placement, are expected to be $225.0 million. The company also sold 1,532,691 common shares and pre-funded warrants worth $50.0 million to Sanofi Foreign Participations B.V. in a private placement. Windwa...

    11-12 23:18